ClinicalTrials.gg
Status unknownNCT05320536Updated Apr 11, 2022

A Clinical Study of Gulingji Capsule in the Treatment of Idiopathic Oligospermia, Asthenia, and Teratozoospermia

A Phase 4 interventional study of Guilingji Capsule and Placebo in Oligospermia, sponsored by Jinling Hospital, China. Status unknown at 4 sites in China. Open to male participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2022-04-11.

Sponsored by Jinling Hospital, China · Phase 4, Interventional, and Treatment

The sponsor has not verified this record recently (last verified Apr 2022), so the status shown — last known as Recruiting — may be out of date.
Phase
Phase 4
Study type
Interventional
Enrollment
240
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
Male
01

Study summary

The object of study for patients with idiopathic disease of OAT, the use of multicenter, randomized, double-blind, controlled, prospective clinical research, choose according to row, standard units of idiopathic male infertility clinics less weak abnormal sperm, randomly divided into experimental group and the placebo group, the comparison between the two groups of patients and semen parameters before and after medication, seminal plasma hormone, serum lipid levels and other indicators;At the same time, serum and seminal plasma samples of the two groups of patients before and after treatment were collected for bioinformatics analysis of protein spectrum to find the effector molecules of Gulingji capsule.

Read the detailed description

The WHO defines infertility as a condition in which a couple cohabitates and has normal sex, has not used contraception for more than a year and the woman has not been able to conceive naturally.Some male infertility patients who cannot find related infertility factors are called idiopathic male infertility.These male infertility patients are often characterized by abnormal sperm count (including oligospermia, azoospermia, occult sperm), abnormal motility (including asthenospermia, asthenospermia), or malformed sperm, collectively referred to as idiopathic oligospermia (idiopathic OAT).

At present, the treatment methods of idiopathic OAT are mostly empirical treatment, including anti-oxidation treatment, treatment to improve cell energy metabolism, treatment to improve microcirculation of the whole body and reproductive system, etc.In general, traditional Chinese treatment should be combined with traditional Chinese medicine.However, the relevant mechanism of TCM treatment of OAT is not yet clear.

The object of study for patients with idiopathic disease of OAT, the use of multicenter, randomized, double-blind, controlled, prospective clinical research, choose according to row, standard units of idiopathic male infertility clinics less weak abnormal sperm, randomly divided into experimental group and the placebo group, the comparison between the two groups of patients and semen parameters before and after medication, seminal plasma hormone, serum lipid levels and other indicators;At the same time, serum and seminal plasma samples of the two groups of patients before and after treatment were collected for bioinformatics analysis of protein spectrum to find the effector molecules of Gulingji capsule.

It is assumed that the probable case loss rate in the trial is 20%, with 120 cases in each group, and a total of 240 cases are required.

Drug treatment: Gulingji capsule was taken orally for 2 capsules, once before breakfast and dinner, and was taken with saline solution. The total treatment period was 90 days.(Placebo is rice flour)

02

Conditions studied

  • Oligospermia

Browse trials for

03

In context

Oligospermia

64 studies on the registry are indexed under Oligospermia; 17 are open to participants now.

This study's planned enrollment of 240 is above the median of 65 across 46 interventional studies indexed under Oligospermia.

Browse Oligospermia studies →

Lead sponsor

Jinling Hospital, China is the lead sponsor of 131 studies on the registry; 35 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Diagnosed as oligoasthenospermia according to the World Health Organization Laboratory Manual for Human Semen Examination and Treatment (5th edition);
  2. initial examination and reexamination of abnormal semen quality shall meet one of the following conditions: sperm density \< 15×10\^6 / mL or total sperm count \< 39×10\^6, proportion of forward motile sperm \< 32% or total sperm viability \< 40%, percentage of normal sperm \< 4%.

Exclusion criteria

Exclusion Criteria:

  1. Leucospermia, with testis, epididymitis, prostatitis, severe genital trauma, testicular torsion, urinary tract infection, cryptorchidism, varicocele, and a history of serious medical conditions such as diabetes, tumor history, inguinal and genital surgery.
  2. Testicular volume \< 12ml (B-ultrasonic measurement).
  3. \< 18.5 or > 32.
  4. Chromosomal karyotype abnormalities.
  5. Patients with endocrine diseases.
  6. Exposure to an occupation or environment with reproductive toxicity.
  7. Drug therapy to improve semen quality has been used in the past 2 weeks.
  8. Hepatobiliary disease, severe renal insufficiency, clinical disease or history of medication known to reduce fertility.
  9. A known or suspected history of allergy to experimental drugs and similar products.
  10. Any circumstance that the investigator considers to be likely to interfere with participation in the study or assessment.
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
240 participants (estimated)

Study arms

  • Experimental
    Experimental group

    Guilingji capsule Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days.

    Drug: Guilingji Capsule

  • Placebo comparator
    Control group

    Placebo Take 2 tablets orally, once before breakfast and dinner, and take them with saline. The total treatment period is 90 days

    Drug: Placebo

Interventions

  • DrugGuilingji Capsule

    This medicine is capsule medicine, take method is oral.

  • DrugPlacebo

    This medicine is capsule medicine(Placebo), take method is oral.

06

What researchers measure

Primary outcomes

  1. TNPMS

    Total sperm count in forward motion

    Time frame: 1 years

Secondary outcomes

  1. DFI

    Sperm DNA fragmentation rate

    Time frame: 1 years

07

Study locations

4 of 4 sites recruiting
  • Center for Reproductive Medicine, Jinling Hospital
    Nanjing, Jiangsu 210000, China
    Recruiting
  • Nanjing Jiangning Hospital
    Nanjing, Jiangsu, China
    Recruiting
    • Tang Qinlai · Contact
  • The First Affiliated Hospital of Wenzhou Medical University
    Wenzhou, Jiangsu, China
    Recruiting
    • Pan Chengshuang · Contact
  • Xi 'an Tangdu Hospital
    Xi'an, Jiangsu, China
    Recruiting
    • Li Jianbo · Contact
08

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Dec 2021 (actual). Primary completion is estimated for Jun 2022, 6 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 23, 2021
First posted
Apr 11, 2022
StartActual
Dec 6, 2021
Primary completionEst.
Jun 30, 2022
CompletionEst.
Dec 31, 2022
Last update
Apr 11, 2022
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 11, 2022, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05320536
Responsible party
Bing Yao (Reproductive Medicine Center, Jinling Hospital, China) — Principal investigator
First posted
Apr 11, 2022
Start date
Dec 6, 2021
Primary completion
Jun 30, 2022 (estimated)
Completion
Dec 31, 2022 (estimated)
Last update
Apr 11, 2022

Study contacts

Yao bing
Contact
yaobing@nju.edu.cn
13815853296

Oversight

FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is status unknown, as verified in Apr 2022. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion